- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02061813
Dermal Safety Study to Evaluate Potential Irritation of Abametapir Lotion
A 21-Day, Randomized, Controlled Study to Evaluate the Irritation Potential of Abametapir Lotion in Healthy Volunteers, Using a Cumulative Irritant Patch Test Design
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This will be a randomized, evaluator-blind, single-center, controlled, within-subject comparison study of the investigational products (abametapir lotion) and its vehicle lotion and positive and negative controls under occlusive conditions in healthy volunteers. All subjects will have the investigational product (abametapir lotion), the vehicle product, the positive control patch, and negative control patch applied to 4 randomly assigned, adjacent skin sites on the infrascapular area of their back, for the purpose of determining irritation potential.
The investigational products, vehicle, and controls will be applied to one side of the infrascapular area of the back. Evaluation of dermal reactions at the application sites will be assessed clinically using a visual scale that rates the degree of erythema, edema, and other signs of cutaneous irritation (see Section 3.5.5).
A total of 21 applications of each product will be made.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
New Jersey
-
Paramus, New Jersey, United States, 07652
- TKL Reserach Inc
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Are healthy (to be confirmed by medical history) males or females, 18 years of age or older;
- In the case of females of childbearing potential, are using an acceptable form of birth control (oral/implant/injectable/transdermal contraceptives, intrauterine device, condom with spermicide, diaphragm with spermicide, abstinence, partner's vasectomy). Abstinence or vasectomized partner are acceptable if the female subject agrees to implement one of the other acceptable methods of birth control if her lifestyle/partner changes;
- If female of childbearing potential, have a negative urine pregnancy test (UPT) at Day 1, and are willing to submit to a pregnancy test at the end of study (EOS);
- Are free of any systemic or dermatologic disorder, which, in the opinion of the investigator, will interfere with the study results or increase the risk of adverse events;
- Are of any skin type or race, providing the skin pigmentation will allow discernment of erythema;
- Complete a patch study Medical Screening form as well as a Medical Personal History form; and
- Read, understand, and provide signed informed consent.
Exclusion Criteria:
- Have any visible skin disease at the application site which, in the opinion of the investigative personnel, will interfere with the evaluation of the test site reaction;
- Are not willing to refrain from using topical/systemic analgesics such as aspirin (daily use of 81 mg aspirin is acceptable), Aleve, Motrin, Advil, or Nuprin for 72 hours prior to and during the study (occasional use of acetaminophen will be permitted);
- Are using inhaled/systemic/topical corticosteroids in the 3 weeks prior to and during the study, or systemic/topical antihistamines for 72 hours prior to and during the study;
- Are using medication which, in the opinion of the investigative personnel, will interfere with the study results, including anti-inflammatory medications;
- Are unwilling or unable to refrain from the use of sunscreens, cosmetics, creams, ointments, lotions, or similar products on the back during the study;
- Have psoriasis and/or active atopic dermatitis/eczema;
- Are females who are pregnant, plan to become pregnant during the study, or are breast-feeding a child;
- Have a known sensitivity to constituents present in the material being evaluated;
- Have damaged skin in or around the test sites, including sunburn, excessively deep tans, uneven skin tones, tattoos, scars, excessive hair, numerous freckles, or other disfigurations of the test site
- Have received treatment for any type of internal cancer within 5 years prior to study entry;
- Have a history of, or are currently being treated for skin cancer;
- Are currently participating in any other clinical trial,
- Have any known sensitivity to adhesives; and/or
- Have received any investigational treatment(s) within 4 weeks prior to study entry.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Abametapir lotion 0.74% w/w
Applied 0.2 mL topically under occlusive condition
|
applied 0.2 mL topically under occlusive condition
|
Placebo Comparator: Vehicle lotion
Applied 0.2 mL topically under occlusive condition
|
|
Other: Sodium Lauryl Sulfate
Positive control applied 0.2 mL topically under occlusive condition
|
Sodium Lauryl Sulfate is prepared as a 0.2% aqueous solution by the site for topical administration, and applied 21 times over consecutive days under occlusive conditions, will serve as a positive control.
|
Other: Saline 0.9%
Negative control applied 0.2 mL topically under occlusive condition
|
A solution of 0.9% saline for topical administration, applied 21 times over consecutive days under occlusive conditions, will serve as a negative control
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Potential of Abametapir Lotion to Cause Irritation After Repeated Topical Application to the Healthy Skin of Humans.
Time Frame: 21 days
|
The evaluation of irritation is based on Modified Berger procedure and is accepted as standard methodology for assessment of cumulative irritation potential.
The assessment of all patch sites for irritation symptoms will be visually assessed by a trained evaluator using the numerical equivalents (0-7) where 0 is the least irritation potential and 7 is the maximum irritation potential.
The scoring will be done on daily basis from baseline through Day 21 visit.
The final reported outcome is a mean of the scores over 21 days.
|
21 days
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Jonathan Dosik, TKL Research, Inc.
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- Ha03-007
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Head Lice
-
Taro Pharmaceuticals USACompletedLice; Head LiceUnited States
-
Topaz Pharmaceuticals IncCompletedPediculus Humanus Capitis (Head Lice)United States
-
Perrigo CSCIRecruiting
-
Infectopharm Arzneimittel GmbHRecruitingPediculosis Capitis | Head Lice Infestation | LiceGermany
-
Dr. Reddy's Laboratories LimitedTKL Research, Inc.; AccelovanceCompletedHead LiceUnited States
-
Topaz Pharmaceuticals IncCompleted
-
Dr. Reddy's Laboratories LimitedSyneos Health; AccelovanceCompletedHead Lice InfestationUnited States
-
Alliance PharmaceuticalsSouth Florida Family Health and Research CentersRecruitingHead Lice | Lice Infestations | Pediculosis CapitisUnited States
-
Perrigo CSCIRecruitingHead Lice InfestationMauritius
-
Boston Scientific CorporationCompletedHead Lice | Pediculus Humanus CapitisUnited States
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States